Switch theme
Sign up to access all valuation multiples
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
2012
114
LTM Revenue $24.9M
LTM EBITDA -$43.2M
$135M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OmniAb has a last 12-month revenue (LTM) of $24.9M and a last 12-month EBITDA of -$43.2M.
In the most recent fiscal year, OmniAb achieved revenue of $26.4M and an EBITDA of -$50.9M.
OmniAb expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OmniAb valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $24.9M | XXX | $26.4M | XXX | XXX | XXX |
| Gross Profit | $24.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$43.2M | XXX | -$50.9M | XXX | XXX | XXX |
| EBITDA Margin | -173% | XXX | -193% | XXX | XXX | XXX |
| EBIT | -$71.6M | XXX | -$74.5M | XXX | XXX | XXX |
| EBIT Margin | -287% | XXX | -282% | XXX | XXX | XXX |
| Net Profit | -$62.9M | XXX | -$62.0M | XXX | XXX | XXX |
| Net Margin | -252% | XXX | -235% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, OmniAb's stock price is $1.
OmniAb has current market cap of $157M, and EV of $135M.
See OmniAb trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $135M | $157M | XXX | XXX | XXX | XXX | $-0.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, OmniAb has market cap of $157M and EV of $135M.
OmniAb's trades at 5.1x EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate OmniAb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OmniAb has a P/E ratio of -2.5x.
See valuation multiples for OmniAb and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $157M | XXX | $157M | XXX | XXX | XXX |
| EV (current) | $135M | XXX | $135M | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | -3.1x | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | -1.9x | XXX | -1.8x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.5x | XXX | -2.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOmniAb's last 12 month revenue growth is 9%
OmniAb's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.9M for the same period.
OmniAb's rule of 40 is -137% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OmniAb's rule of X is -151% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OmniAb and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | -173% | XXX | -193% | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -137% | XXX | -184% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -151% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 209% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 382% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OmniAb acquired XXX companies to date.
Last acquisition by OmniAb was XXXXXXXX, XXXXX XXXXX XXXXXX . OmniAb acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OmniAb founded? | OmniAb was founded in 2012. |
| Where is OmniAb headquartered? | OmniAb is headquartered in United States of America. |
| How many employees does OmniAb have? | As of today, OmniAb has 114 employees. |
| Who is the CEO of OmniAb? | OmniAb's CEO is Mr. Matthew W. Foehr. |
| Is OmniAb publicy listed? | Yes, OmniAb is a public company listed on NAS. |
| What is the stock symbol of OmniAb? | OmniAb trades under OABI ticker. |
| When did OmniAb go public? | OmniAb went public in 2022. |
| Who are competitors of OmniAb? | Similar companies to OmniAb include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of OmniAb? | OmniAb's current market cap is $157M |
| What is the current revenue of OmniAb? | OmniAb's last 12 months revenue is $24.9M. |
| What is the current revenue growth of OmniAb? | OmniAb revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of OmniAb? | Current revenue multiple of OmniAb is 5.4x. |
| Is OmniAb profitable? | Yes, OmniAb is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OmniAb? | OmniAb's last 12 months EBITDA is -$43.2M. |
| What is OmniAb's EBITDA margin? | OmniAb's last 12 months EBITDA margin is -173%. |
| What is the current EV/EBITDA multiple of OmniAb? | Current EBITDA multiple of OmniAb is -3.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
